Literature DB >> 28462395

Calmodulin and PI3K Signaling in KRAS Cancers.

Ruth Nussinov1,2, Guanqiao Wang3, Chung-Jung Tsai1, Hyunbum Jang1, Shaoyong Lu3, Avik Banerjee4, Jian Zhang3, Vadim Gaponenko4.   

Abstract

Calmodulin (CaM) uniquely promotes signaling of oncogenic K-Ras; but not N-Ras or H-Ras. How CaM interacts with K-Ras and how this stimulates cell proliferation are among the most challenging questions in KRAS-driven cancers. Earlier data pointed to formation of a ternary complex consisting of K-Ras, PI3Kα and CaM. Recent data point to phosphorylated CaM binding to the SH2 domains of the p85 subunit of PI3Kα and activating it. Modeling suggests that the high affinity interaction between the phosphorylated CaM tyrosine motif and PI3Kα, can promote full PI3Kα activation by oncogenic K-Ras. Our up-to-date review discusses CaM's role in PI3K signaling at the membrane in KRAS-driven cancers. This is significant since it may help development of K-Ras-specific pharmacology.

Entities:  

Keywords:  K-Ras; calcium; drug discovery; phosphorylated tyrosine motif; plasma membrane; proliferation

Mesh:

Substances:

Year:  2017        PMID: 28462395      PMCID: PMC5408465          DOI: 10.1016/j.trecan.2017.01.007

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  87 in total

1.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

2.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

3.  Alteration of calmodulin-protein interactions by a monoclonal antibody to calmodulin.

Authors:  D B Sacks
Journal:  Biochim Biophys Acta       Date:  1994-05-18

4.  Calmodulin as substrate for insulin-receptor kinase. Phosphorylation by receptors from rat skeletal muscle.

Authors:  D B Sacks; J M McDonald
Journal:  Diabetes       Date:  1989-01       Impact factor: 9.461

5.  K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.

Authors:  B Alvarez-Moya; C López-Alcalá; M Drosten; O Bachs; N Agell
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

6.  Subtoxic N-methyl-D-aspartate delayed neuronal death in ischemic brain injury through TrkB receptor- and calmodulin-mediated PI-3K/Akt pathway activation.

Authors:  Jing Xu; Quan-Guang Zhang; Chong Li; Guang-Yi Zhang
Journal:  Hippocampus       Date:  2007       Impact factor: 3.899

7.  Glial cell line-derived neurotrophic factor increases intracellular calcium concentration. Role of calcium/calmodulin in the activation of the phosphatidylinositol 3-kinase pathway.

Authors:  M José Pérez-García; Valentín Ceña; Yolanda de Pablo; Marta Llovera; Joan X Comella; Rosa M Soler
Journal:  J Biol Chem       Date:  2003-11-20       Impact factor: 5.157

Review 8.  Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.

Authors:  Oscar Vadas; John E Burke; Xuxiao Zhang; Alex Berndt; Roger L Williams
Journal:  Sci Signal       Date:  2011-10-18       Impact factor: 8.192

9.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

10.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

View more
  27 in total

1.  The structural basis for Ras activation of PI3Kα lipid kinase.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2019-06-05       Impact factor: 3.676

Review 2.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

Review 3.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

4.  Ca2+-Dependent Switch of Calmodulin Interaction Mode with Tandem IQ Motifs in the Scaffolding Protein IQGAP1.

Authors:  Mingzhen Zhang; Zhigang Li; Hyunbum Jang; Andrew C Hedman; David B Sacks; Ruth Nussinov
Journal:  Biochemistry       Date:  2019-11-26       Impact factor: 3.162

5.  PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization.

Authors:  Serena Muratcioglu; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2017-06-07       Impact factor: 2.991

Review 6.  Allostery, and how to define and measure signal transduction.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Biophys Chem       Date:  2022-01-29       Impact factor: 2.352

7.  Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains.

Authors:  Mingzhen Zhang; Hyunbum Jang; Vadim Gaponenko; Ruth Nussinov
Journal:  Biophys J       Date:  2017-11-07       Impact factor: 4.033

8.  Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.

Authors:  Mingzhen Zhang; Zhigang Li; Guanqiao Wang; Hyunbum Jang; David B Sacks; Jian Zhang; Vadim Gaponenko; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2018-08-08       Impact factor: 2.991

9.  KRAS Activating Signaling Triggers Arteriovenous Malformations.

Authors:  Feixiong Cheng; Ruth Nussinov
Journal:  Trends Biochem Sci       Date:  2018-05-07       Impact factor: 13.807

10.  Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma.

Authors:  Xu Hannah Zhang; Jack Hsiang; Steven T Rosen
Journal:  J Clin Haematol       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.